A recent study reveals that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who stop conventional diet and exercise programs.
Research printed in a prominent medical journal points out that while overweight people can lose about a fifth of their total mass while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using such treatments should be cognizant of the risk of quick rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight within about 18 months.
Analyzing Approaches
The study, which reviewed dozens of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with other pills.
Scientists emphasize that people who shed pounds through dieting usually have a more gradual weight regain—around 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Nutrition scientists suggest the mechanism of the injections accounts for the amplified rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating far more likely."
A Chronic Disease?
Health authorities suggest the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals contend that, due to the high risk of relapse, the treatment should be considered ongoing.
This view is supported by drug manufacturers, who say that the results "underscore the persistent character of excess weight," similar to managing conditions like diabetes.
Patient Accounts
Users who have stopped the medication report a intense return of hunger.
"I experienced something that goes on and you become starving," recalled one woman.
This challenge is worsened if patients have not developed sustainable lifestyle or habit modifications during treatment.
Significant Adoption
Recent estimates show that a significant number of people in the UK have used these injections in the past year, with interest remaining high.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, experts stress that while these medications are potent tools for weight loss, they are not a magic fix and lasting health benefits likely depends on ongoing behavioural support.
